DBV Technologies | DBVT - Ebitda



DBV Technologies reported $-39036000 in EBITDA for its fiscal quarter ending in June of 2025.


Ebitda Change Date
Acadia Pharmaceuticals USD 35.31M 13.07M Jun/2025
Alnylam Pharmaceuticals USD 18.83M 13.65M Jun/2025
Amarin USD -16025000 714K Mar/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
DBV Technologies USD -39036000 16.89M Jun/2025
Halozyme Therapeutics USD 225.5M 63.51M Jun/2025
Incyte USD 581.52M 358.87M Jun/2025
Insmed USD -297127000 71.11M Jun/2025
Ionis Pharmaceuticals USD 150.23M 291.7M Jun/2025
Neurocrine Biosciences USD 152.9M 121.6M Jun/2025
PTC Therapeutics USD 971.14M 970.07M Mar/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -91344000 35.09M Jun/2025
United Therapeutics USD 436.8M 34.2M Jun/2025